In Silico | GenomeWeb

In Silico

Premium

www.GenomeWeb.COM Daily

 

Tool Talk

 

As big pharma’s product pipeline continues to wither, the role of genomics tools and data providers becomes increasingly uncertain. Will the pressure on pharma firms mean that genomic companies can expect an increase in new-technology orders? Or will pharma’s revenue woes mean increased spending becomes foolish?

 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.